RecruitingNot ApplicableNCT05710380

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

Magnetic Resonance Imaging (MRI) Derived Quantitative Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

Sponsor

University of Chicago

Enrollment

180 participants

Start Date

Apr 26, 2023

Study Type

INTERVENTIONAL

Conditions

Prostate Cancer Prostate Neoplasm Prostate Adenocarcinoma

Summary

Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that allow doctors to visualize the body's internal structures) of the prostate. Participation in this research will last about 12 months. There is a one-time MRI and 1-2 biopsies and then the investigator would like to follow the participant's progress.

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating whether MRI-based risk maps — specialized images that highlight the areas most likely to contain cancer — can improve the accuracy of prostate biopsies guided by MRI-ultrasound fusion technology. **You may be eligible if...** - You have known or suspected prostate cancer and have been referred for a prostate MRI followed by a biopsy - You are able to give written informed consent **You may NOT be eligible if...** - You are unable to give informed consent - You cannot follow the study procedures for any reason - You have a psychiatric condition that affects your ability to consent independently - You are under 18 - You are incarcerated - You have previously been treated for prostate cancer (surgery, radiation, hormone therapy, or ablation) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERRisk Map Decision Support System (DSS).

The Risk Map DSS tool is an image analysis software that automatically interprets images of the prostate that were captured using an MR (magnetic resonance) scanner (an imaging technique that uses scanners to take pictures of the body). This tool can potentially identify additional areas of cancer in your prostate that may have otherwise been missed.

RADIATIONMagnetic Resonance Imaging (MRI)

A medical imaging test that uses a large machine/scanner to take images of the body and internal organs and structures.

PROCEDUREMagnetic Resonance Imaging (MRI) Guided Biopsy

A removal of tumor tissue from the body based on images of the prostate provided by a previous magnetic resonance imaging (MRI) test. Up to 2 biopsies on trial.

Locations(1)

University of Chicago Medicine Comprehensive Cancer Center

Chicago, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05710380

Related Trials

Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer

NCT046926751 location

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

NCT0700515433 locations

DESTINY-PANTUMOUR04

NCT0712400017 locations

Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System

NCT068073593 locations

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

NCT0733644618 locations